🌍 We continue to expand our Intellectual Property Portfolio around the globe, expanding our Freedom-to-Operate capacity and creating new shareholder value.
We are pleased to share exciting news regarding our intellectual property portfolio. Cytonics Corporation has been granted United States Patent No. US 12,195,521 B2 titled “Therapeutic Variant Alpha-2-Macroglobulin Compositions.”
Patent Overview
This newly issued patent covers:
- A2M polypeptide compositions containing a non-natural bait region (i.e., our engineered A2M variant, CYT-108)
- Methods for producing both wild-type and variant A2M polypeptides (e.g., the genetic engineering process).
- Polypeptides containing a non-natural bait region with enhanced protease inhibitory characteristics
- Longer half-lives upon administration compared to wild-type A2M
Strategic Significance
This patent significantly strengthens our freedom-to-operate strategy in several important ways:
- Expanded Therapeutic Applications: The patent covers compositions useful in treating inflammation, chronic wounds, and diseases associated with proteases, broadening our market potential beyond our current focus areas.
- Enhanced Competitive Position: The non-natural bait region technology provides advantages over wild-type A2M, giving us critical differentiation in the marketplace.
- Extended Exclusivity: With this patent issuance (filed March 6, 2023), we secure protection for our novel A2M technology for approximately two decades.
- Building on Previous Success: This patent is a division of prior applications dating back to 2014, demonstrating our consistent innovation and strategic IP development.
Value Creation
This patent issuance strengthens Cytonics’ valuation by:
- Strengthening Barriers to Entry: Our robust patent portfolio makes it more difficult for competitors to enter our space without infringing on our protected technologies.
- Expanding Licensing Opportunities: The broader claims provide additional avenues for potential licensing and partnership agreements.
- Supporting Funding Initiatives: A stronger IP position enhances our attractiveness to investors as we pursue our next growth phase.
- Enabling New Product Development: The protected technology supports our pipeline development of next-generation therapeutic products.
This achievement results from the outstanding work of our inventors Lewis Hanna, John David Laughlin, and Shawn Robert Browning, along with our dedicated R&D team.
We remain committed to building shareholder value through strategic IP development and will continue to provide updates on our progress in commercializing this technology.
Thank you for your continued support and investment in Cytonics’ vision!
Appreciatively,
Joey Bose
President & CEO
Forward Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the progress of and plans related to the Company’s product candidates, clinical studies and preclinical research and development programs, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress and timelines. These and any other forward-looking statements in this release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and the risk that the Company may incur operating expenses in amounts greater than anticipated. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission (https://www.sec.gov/edgar/browse/?CIK=0001421744), including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Cytonics Corporation is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
